KR100591805B1 - 아자트리시클로[3.3.1.1]데칸 유도체 및 이들을 함유한의약 조성물 - Google Patents

아자트리시클로[3.3.1.1]데칸 유도체 및 이들을 함유한의약 조성물 Download PDF

Info

Publication number
KR100591805B1
KR100591805B1 KR1020007008963A KR20007008963A KR100591805B1 KR 100591805 B1 KR100591805 B1 KR 100591805B1 KR 1020007008963 A KR1020007008963 A KR 1020007008963A KR 20007008963 A KR20007008963 A KR 20007008963A KR 100591805 B1 KR100591805 B1 KR 100591805B1
Authority
KR
South Korea
Prior art keywords
compound
pyridyl
delete delete
aza
compounds
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
KR1020007008963A
Other languages
English (en)
Korean (ko)
Other versions
KR20010052173A (ko
Inventor
벤치리프메로우엔
립피엘로파트릭마이클
크룩크스피터안토니
박해일
바하티발윈더싱
칼드웰윌리암스커트
둘게리마우라이스
Original Assignee
타가셉트 인코포레이티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US09/054,175 external-priority patent/US5952339A/en
Priority claimed from US09/053,937 external-priority patent/US6057446A/en
Application filed by 타가셉트 인코포레이티드 filed Critical 타가셉트 인코포레이티드
Publication of KR20010052173A publication Critical patent/KR20010052173A/ko
Application granted granted Critical
Publication of KR100591805B1 publication Critical patent/KR100591805B1/ko
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/18—Bridged systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
KR1020007008963A 1998-04-02 1999-03-03 아자트리시클로[3.3.1.1]데칸 유도체 및 이들을 함유한의약 조성물 Expired - Fee Related KR100591805B1 (ko)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US09/054,175 US5952339A (en) 1998-04-02 1998-04-02 Pharmaceutical compositions and methods of using nicotinic antagonists for treating a condition or disorder characterized by alteration in normal neurotransmitter release
US9/053,937 1998-04-02
US09/053,937 US6057446A (en) 1998-04-02 1998-04-02 Certain 1-aza-tricyclo [3.3.1-13,7 ] decane compounds
US09/054,175 1998-04-02
US09/053,937 1998-04-02
US9/054,175 1998-04-02

Publications (2)

Publication Number Publication Date
KR20010052173A KR20010052173A (ko) 2001-06-25
KR100591805B1 true KR100591805B1 (ko) 2006-06-26

Family

ID=26732410

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020007008963A Expired - Fee Related KR100591805B1 (ko) 1998-04-02 1999-03-03 아자트리시클로[3.3.1.1]데칸 유도체 및 이들을 함유한의약 조성물

Country Status (13)

Country Link
EP (1) EP1068208B1 (enExample)
JP (1) JP2002510690A (enExample)
KR (1) KR100591805B1 (enExample)
AT (1) ATE240331T1 (enExample)
AU (1) AU2892999A (enExample)
BR (1) BR9907172A (enExample)
CA (1) CA2317567A1 (enExample)
DE (1) DE69907894T2 (enExample)
DK (1) DK1068208T3 (enExample)
ES (1) ES2199561T3 (enExample)
MX (1) MXPA00009634A (enExample)
PT (1) PT1068208E (enExample)
WO (1) WO1999051602A1 (enExample)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6953855B2 (en) 1998-12-11 2005-10-11 Targacept, Inc. 3-substituted-2(arylalkyl)-1-azabicycloalkanes and methods of use thereof
US6432975B1 (en) * 1998-12-11 2002-08-13 Targacept, Inc. Pharmaceutical compositions and methods for use
US6809105B2 (en) 2000-04-27 2004-10-26 Abbott Laboratories Diazabicyclic central nervous system active agents
MY137020A (en) * 2000-04-27 2008-12-31 Abbott Lab Diazabicyclic central nervous system active agents
WO2001082978A2 (en) * 2000-05-01 2001-11-08 Targacept, Inc. Imaging of nicotinic acetylcholine receptor subtypes
US7897766B2 (en) 2005-09-23 2011-03-01 Abbott Laboratories Amino-aza-adamantane derivatives and methods of use
US8314119B2 (en) * 2006-11-06 2012-11-20 Abbvie Inc. Azaadamantane derivatives and methods of use
US8163914B2 (en) 2007-03-23 2012-04-24 Abbott Laboratories Acetamide and carboxamide derivatives of azaadamantane and methods of use thereof
CN101641357B (zh) 2007-03-23 2013-09-18 Abbvie公司 4-取代的氮杂金刚烷衍生物及其使用方法
SA08290475B1 (ar) 2007-08-02 2013-06-22 Targacept Inc (2s، 3r)-n-(2-((3-بيردينيل)ميثيل)-1-آزا بيسيكلو[2، 2، 2]أوكت-3-يل)بنزو فيوران-2-كربوكساميد، وصور أملاحه الجديدة وطرق استخدامه
TW201031664A (en) 2009-01-26 2010-09-01 Targacept Inc Preparation and therapeutic applications of (2S,3R)-N-2-((3-pyridinyl)methyl)-1-azabicyclo[2.2.2]oct-3-yl)-3,5-difluorobenzamide
US9464078B2 (en) 2010-09-23 2016-10-11 Abbvie Inc. Monohydrate of azaadamantane derivatives
US9724340B2 (en) 2015-07-31 2017-08-08 Attenua, Inc. Antitussive compositions and methods

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL107184A (en) * 1992-10-09 1997-08-14 Abbott Lab Heterocyclic ether compounds that enhance cognitive function
US5597919A (en) * 1995-01-06 1997-01-28 Dull; Gary M. Pyrimidinyl or Pyridinyl alkenyl amine compounds
US5585388A (en) * 1995-04-07 1996-12-17 Sibia Neurosciences, Inc. Substituted pyridines useful as modulators of acetylcholine receptors
US5583140A (en) * 1995-05-17 1996-12-10 Bencherif; Merouane Pharmaceutical compositions for the treatment of central nervous system disorders
JP3510937B2 (ja) * 1995-06-05 2004-03-29 ポリプラスチックス株式会社 耐熱性ポリエステルアミドスルフィド樹脂及びその組成物
JPH11508540A (ja) * 1995-06-29 1999-07-27 ノボ ノルディスク アクティーゼルスカブ 新規の置換アザ環式またはアザ二環式化合物
EP0853621A1 (en) * 1995-09-22 1998-07-22 Novo Nordisk A/S Novel substituted azacyclic or azabicyclic compounds

Also Published As

Publication number Publication date
EP1068208B1 (en) 2003-05-14
EP1068208A1 (en) 2001-01-17
KR20010052173A (ko) 2001-06-25
DE69907894T2 (de) 2004-03-11
DE69907894D1 (de) 2003-06-18
WO1999051602A1 (en) 1999-10-14
BR9907172A (pt) 2000-10-10
JP2002510690A (ja) 2002-04-09
DK1068208T3 (da) 2003-09-01
MXPA00009634A (es) 2005-06-20
PT1068208E (pt) 2003-09-30
ES2199561T3 (es) 2004-02-16
ATE240331T1 (de) 2003-05-15
AU2892999A (en) 1999-10-25
CA2317567A1 (en) 1999-10-14

Similar Documents

Publication Publication Date Title
US5952339A (en) Pharmaceutical compositions and methods of using nicotinic antagonists for treating a condition or disorder characterized by alteration in normal neurotransmitter release
USRE41439E1 (en) Pharmaceutical compositions and methods for use
US6057446A (en) Certain 1-aza-tricyclo [3.3.1-13,7 ] decane compounds
AU2008258188A1 (en) Arylvinylazacycloalkane compounds and methods of preparation and use thereof
KR100591805B1 (ko) 아자트리시클로[3.3.1.1]데칸 유도체 및 이들을 함유한의약 조성물
KR100613050B1 (ko) 아자 삼환식 화합물
US6624167B1 (en) Pharmaceutical compositions and methods for use
US6579878B1 (en) Pharmaceutical compositions and methods for use
AU2007200997A1 (en) Azabicyclic derivatives and their therapeutic use

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

A201 Request for examination
P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

N231 Notification of change of applicant
PN2301 Change of applicant

St.27 status event code: A-3-3-R10-R13-asn-PN2301

St.27 status event code: A-3-3-R10-R11-asn-PN2301

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

GRNT Written decision to grant
PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

R17-X000 Change to representative recorded

St.27 status event code: A-5-5-R10-R17-oth-X000

LAPS Lapse due to unpaid annual fee
PC1903 Unpaid annual fee

St.27 status event code: A-4-4-U10-U13-oth-PC1903

Not in force date: 20090614

Payment event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

PC1903 Unpaid annual fee

St.27 status event code: N-4-6-H10-H13-oth-PC1903

Ip right cessation event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

Not in force date: 20090614

P22-X000 Classification modified

St.27 status event code: A-4-4-P10-P22-nap-X000

PN2301 Change of applicant

St.27 status event code: A-5-5-R10-R13-asn-PN2301

St.27 status event code: A-5-5-R10-R11-asn-PN2301